Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the Dow Jones Industrial Average ( ^DJI) trading up 4 points (0.0%) at 17,515 as of Tuesday, Jan. 20, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,216 issues advancing vs. 1,900 declining with 118 unchanged.

The Drugs industry as a whole closed the day down 0.1% versus the S&P 500, which was up 0.2%. Top gainers within the Drugs industry included ImmuCell ( ICCC), up 6.9%, China Pharma ( CPHI), up 6.9%, Auris Medical ( EARS), up 3.5%, Ruthigen ( RTGN), up 1.8% and Cellectar Biosciences ( CLRB), up 2.6%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Ruthigen ( RTGN) is one of the companies that pushed the Drugs industry higher today. Ruthigen was up $0.07 (1.8%) to $3.93 on light volume. Throughout the day, 11,221 shares of Ruthigen exchanged hands as compared to its average daily volume of 16,500 shares. The stock ranged in a price between $3.56-$4.00 after having opened the day at $3.92 as compared to the previous trading day's close of $3.86.

Ruthigen has a market cap of $18.5 million and is part of the health care sector. Shares are up 10.3% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Auris Medical ( EARS) was up $0.13 (3.5%) to $3.88 on heavy volume. Throughout the day, 16,905 shares of Auris Medical exchanged hands as compared to its average daily volume of 9,800 shares. The stock ranged in a price between $3.80-$4.05 after having opened the day at $4.05 as compared to the previous trading day's close of $3.75.

Auris Medical has a market cap of $108.6 million and is part of the health care sector. Shares are down 3.9% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

China Pharma ( CPHI) was another company that pushed the Drugs industry higher today. China Pharma was up $0.02 (6.9%) to $0.31 on light volume. Throughout the day, 4,208 shares of China Pharma exchanged hands as compared to its average daily volume of 74,900 shares. The stock ranged in a price between $0.29-$0.31 after having opened the day at $0.29 as compared to the previous trading day's close of $0.29.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. China Pharma has a market cap of $12.6 million and is part of the health care sector. Shares are down 3.4% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate China Pharma a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates China Pharma as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and poor profit margins.

Highlights from TheStreet Ratings analysis on CPHI go as follows:

  • CHINA PHARMA HOLDINGS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, CHINA PHARMA HOLDINGS INC swung to a loss, reporting -$0.45 versus $0.10 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 174.9% when compared to the same quarter one year ago, falling from -$2.30 million to -$6.33 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, CHINA PHARMA HOLDINGS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to $0.18 million or 71.56% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The gross profit margin for CHINA PHARMA HOLDINGS INC is currently lower than what is desirable, coming in at 34.60%. Regardless of CPHI's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, CPHI's net profit margin of -113.66% significantly underperformed when compared to the industry average.

You can view the full analysis from the report here: China Pharma Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.